Skip to main content

Table 3 Utility and utility decrements associated with health states and treatments included in the model (measured by EQ-5D) from reference 30

From: Estimation of the cost-effectiveness of apixaban versus vitamin K antagonists in the management of atrial fibrillation in Argentina

Health State Utility (SE)
Non-valvular atrial fibrillation 0.7270 (0.0095)
Stroke (ischemic or hemorrhagic) 0.6151 (0.0299)
Mild 0.5646 (0.0299)
  0.5142 (0.0299)
Moderate  
Severe 0.6151 (0.0299)
Myocardial infarction 0.5646 (0.0299)
  0.6265 (0.0299)
Females  
Males  
Systemic embolism  
Transient health states/anticoagulation use Utility decrements (SE/95 % CI)
Other intracranial haemorrhage 0.1511 (0.0401)
Other major 0.1511 (0.0401)
Clinically relevant non-major bleed 0.0582 (0.0173)
Other cardiovascular hospitalization 0.1276 (0.0259)
Use of Apixaban or aspirin 0.0020 (0.00-0.04)
Use of Warfarin 0.0120 (0.00-0.08)